Asunto(s)
Hipersensibilidad/tratamiento farmacológico , Enfermedades Respiratorias/tratamiento farmacológico , Agonistas Adrenérgicos beta/uso terapéutico , Antagonistas Colinérgicos/uso terapéutico , Humanos , Hidrocarburos Fluorados , Hipersensibilidad/diagnóstico , Enfermedades Respiratorias/diagnósticoRESUMEN
The National Asthma Education and Prevention Program's (NAEPP) revised guidelines, the Expert Panel Report 3 (EPR-3), published in 2007, represents a shift in the approach to asthma: the EPR-3 recommends that clinicians think of asthma as a chronic disease with an inflammatory basis. EPR-3 guidelines also represent a shift in the treatment paradigm for asthma in line with the shift in approach: although symptomatic relief is still necessary, the primary goal of asthma treatment is now long-term control, with the aim of minimizing exacerbation frequency and severity and limiting possible permanent airway damage that can result from frequent asthma exacerbations. To help clinicians implement the new EPR-3 guidelines into daily practice, the NAEPP's Guidelines Implementation Panel has identified 6 key action-focused recommendations. This article describes those recommendations and the evidence supporting them.
Asunto(s)
Asma/tratamiento farmacológico , Asma/prevención & control , Educación del Paciente como Asunto/métodos , Guías de Práctica Clínica como Asunto , Antiasmáticos/uso terapéutico , Antiinflamatorios/uso terapéutico , Broncodilatadores/uso terapéutico , Enfermedad Crónica , Comorbilidad , Vías de Administración de Medicamentos , Ambiente , Humanos , Inflamación/tratamiento farmacológico , Inflamación/prevención & control , Pruebas de Función Respiratoria , Índice de Severidad de la EnfermedadAsunto(s)
Agonistas Adrenérgicos beta/administración & dosificación , Albuterol/análogos & derivados , Androstadienos/administración & dosificación , Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Administración por Inhalación , Corticoesteroides/administración & dosificación , Albuterol/administración & dosificación , Esquema de Medicación , Fluticasona , Humanos , Xinafoato de SalmeterolRESUMEN
BACKGROUND: Oropharyngeal adverse events associated with inhaled corticosteroid (ICS) use can affect adherence; however, these effects have been studied less extensively than those that occur systemically. OBJECTIVE: To calculate the risk of ICS-induced oral candidiasis, dysphonia, and pharyngitis among currently available therapies and to determine related effects of dose and device. METHODS: A computerized search in MEDLINE (January 1966 to June 2004) and EMBASE (January 1974 to June 2004) was conducted using indexed MedDRA terms for oropharyngeal adverse events. Odds ratios (ORs) were used to determine the rate of ICS-induced adverse events based on dose and device. RESULTS: A total of 23 studies (59 drug arms) were evaluated. Incidence of oral candidiasis (P < or = .001), dysphonia (P < or = .001), and pharyngitis (P < or = .023) increased significantly with dose vs placebo at all dose levels and combined, regardless of device. Overall, the ICS metered-dose inhaler (MDI) device (hydrofluoroalkane formulation, 4 arms; chlorofluorocarbon formulation, 26 arms) was associated with a 5-fold greater risk of oral candidiasis vs MDI placebo (OR, 5.40). In contrast, the ICS dry-powder inhaler (DPI) device had a 3-fold greater risk for oral candidiasis vs DPI placebo (OR, 3.24). A similar trend was observed with regard to dysphonia (ICS MDI: OR, 5.68; ICS DPI: OR, 3.74; both vs. placebo). Both ICS MDI and DPI were associated with an approximately 2-fold greater risk of pharyngitis compared with placebo. CONCLUSIONS: Currently available inhaled corticosteroids canbe associated with oropharyngeal adverse events. Such events may be reduced by postdose mouth rinsing or use of a spacer.